BAP1-related signature predicts benefits from immunotherapy over VEGFR/mTOR inhibitors in ccRCC: a retrospective analysis of JAVELIN Renal 101 and checkmate-009/010/025 trials
Kan Liu, Yan Huang, Yu Xu, Guoqiang Wang, Shangli Cai, Xu Zhang, Taoping Shi
Topics & Concepts
NivolumabSunitinibMedicineAxitinibClear cell renal cell carcinomaOncologyBAP1EverolimusRenal cell carcinomaInternal medicineAvelumabKidney cancerImmunotherapyCancerRenal cell carcinoma treatmentCancer Immunotherapy and BiomarkersFerroptosis and cancer prognosis